Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) EPS (Weighted Average and Diluted) (2020 - 2025)

Historic EPS (Weighted Average and Diluted) for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to -$0.18.

  • Keros Therapeutics' EPS (Weighted Average and Diluted) rose 8723.4% to -$0.18 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.56, marking a year-over-year increase of 12994.24%. This contributed to the annual value of -$5.0 for FY2024, which is 376.15% up from last year.
  • Latest data reveals that Keros Therapeutics reported EPS (Weighted Average and Diluted) of -$0.18 as of Q3 2025, which was up 8723.4% from -$0.76 recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $3.62 in Q1 2025 and a low of -$1.41 during Q3 2024
  • Its 5-year average for EPS (Weighted Average and Diluted) is -$0.75, with a median of -$1.1 in 2022.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 26984.59% in 2022, then surged by 39917.36% in 2025.
  • Over the past 5 years, Keros Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.3 in 2021, then crashed by 269.85% to -$1.1 in 2022, then dropped by 21.82% to -$1.34 in 2023, then rose by 8.25% to -$1.23 in 2024, then surged by 85.36% to -$0.18 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.18 for Q3 2025, versus -$0.76 for Q2 2025 and $3.62 for Q1 2025.